Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Samsara BioCapital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 100
Average round size
The average size of a deal this fund participated in
Portfolio companies 82
Rounds per year 14.29
Lead investments 8
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 29
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical

The main department of described Corporate Investor is located in the Palo Alto. The company was established in North America in United States.

The real fund results show that this Corporate Investor is 0 percentage points less often commits exit comparing to other companies. Opposing the other organizations, this Samsara BioCapital works on 1 percentage points more the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 50 - 100 millions dollars. The important activity for fund was in 2019. The increased amount of exits for fund were in 2019.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Samsara BioCapital, startups are often financed by Alta Partners, Skyline Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Redmile Group, EcoR1 Capital, Cormorant Asset Management. In the next rounds fund is usually obtained by UBS Oncology Impact Fund, Redmile Group, EcoR1 Capital.

The overall number of key employees were 2.

We can highlight the next thriving fund investment areas, such as Clinical Trials, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline ElevateBio, ElevateBio, AlloVir For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Samsara BioCapital:
Typical Co-investors
Samsara BioCapital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Samsara BioCapital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Arno Capital Israel, Ramat Gan, Tel Aviv
Chelsea Vanguard Fund -
Colour Life Services Group China, Guangdong, Shenzhen
Drake Management New York, Nyack, United States
First Check Ventures -
Frontline Ventures England, London, United Kingdom
Grupo Picking Pack -
Hallador Investment Advisors -
Hamilton Ventures LLC Atlanta, Georgia, United States
Hargreave Hale England, London, United Kingdom
Huaxin Zhongcheng Investment China, Guangdong, Tianjin
Kloeckner & Co Duisburg, Germany, Nordrhein-Westfalen
MOGU China, Hangzhou, Zhejiang
Nirvana Capital Beijing, Beijing, China
Otter Media California, Santa Monica, United States
Sands Brothers Asset Management New York, New York, United States
Shenzhen Huijing Tongda Business Consulting China, Guangdong, Shenzhen
Tennant Capital Partners Missouri, Saint Louis, United States
UNT Group -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Palvella Therapeutics

Health Care
Life Science
$37M05 Jan 2023 Radnor Township, Pennsylvania, United States

Alpha9 Theranostics

Product Research
$75M14 Dec 2022 Vancouver, British Columbia, Canada

Enlaza Therapeutics

Health Care
$61M12 Oct 2022 La Jolla, California, United States

immatics biotechnologies

$110M10 Oct 2022 Germany, Baden-Württemberg, Germany


Health Care
$300M13 Sep 2022 Los Angeles, California, United States

Autobahn Therapeutics

Health Care
Life Science
$32M08 Sep 2022 San Diego, California, United States

Delfi Diagnostics

Health Care
Health Diagnostics
$225M18 Jul 2022 Baltimore, Maryland, United States


Life Science
$109M29 Jun 2022 Oxford, England, United Kingdom

Scholar Rock

$205M17 Jun 2022 Cambridge, Massachusetts, United States
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Samsara BioCapital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: